Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients

High myopia is an ophthalmic pathology that affects half of the young adults in the United States and Europe and it is predicted that a third of the world’s population could be nearsighted at the end of this decade. It is characterized by at least 6 diopters or axial length > 26 mm and, choroidal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	David Blánquez-Martínez, Xando Díaz-Villamarín, Alba Antúnez-Rodríguez, Ana Pozo-Agundo, José Ignacio Muñoz-Ávila, Luis Javier Martínez-González, Cristina Lucía Dávila-Fajardo
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	myopia pharmacogenetic genetic polymorphism personalized medicine ranibizumab anti-VEGF Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/4adc7064e37c439eaf52b26c7a335386
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4adc7064e37c439eaf52b26c7a335386
record_format	dspace
spelling	oai:doaj.org-article:4adc7064e37c439eaf52b26c7a3353862021-11-25T18:42:35ZGenetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients10.3390/pharmaceutics131119731999-4923https://doaj.org/article/4adc7064e37c439eaf52b26c7a3353862021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1973https://doaj.org/toc/1999-4923High myopia is an ophthalmic pathology that affects half of the young adults in the United States and Europe and it is predicted that a third of the world’s population could be nearsighted at the end of this decade. It is characterized by at least 6 diopters or axial length > 26 mm and, choroidal neovascularization (CNV) in 5 to 11% of cases. Ranibizumab is a recombinant humanized monoclonal antibody fragment. It is an anti-vascular endothelial growth factor (anti-VEGF) drug used in the treatment of CNV. Many genetic polymorphisms have been associated with interindividual differences in the response to ranibizumab, but these associations were not yet assessed among patients with high myopia and CNV. We performed a retrospective study assessing the association of genetic polymorphisms with response to ranibizumab in patients with CNV secondary to high myopia (mCNV). We included genetic polymorphisms previously associated with the response to drugs used in CNV patients (bevacizumab, ranibizumab, aflibercept, and photodynamic therapy (PDT)). We also included genetic variants in the <i>VEGFA</i> gene. Based on our results, <i>ARMS2</i> (rs10490924) and <i>CFH</i> (rs1061170) are associated with response to ranibizumab in high myopia patients; and, included <i>VEGFA</i> genetic polymorphisms are not associated with ranibizumab response in our population but might be related to a higher risk of CNV.David Blánquez-MartínezXando Díaz-VillamarínAlba Antúnez-RodríguezAna Pozo-AgundoJosé Ignacio Muñoz-ÁvilaLuis Javier Martínez-GonzálezCristina Lucía Dávila-FajardoMDPI AGarticlemyopiapharmacogeneticgenetic polymorphismpersonalized medicineranibizumabanti-VEGFPharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1973, p 1973 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	myopia pharmacogenetic genetic polymorphism personalized medicine ranibizumab anti-VEGF Pharmacy and materia medica RS1-441
spellingShingle	myopia pharmacogenetic genetic polymorphism personalized medicine ranibizumab anti-VEGF Pharmacy and materia medica RS1-441 David Blánquez-Martínez Xando Díaz-Villamarín Alba Antúnez-Rodríguez Ana Pozo-Agundo José Ignacio Muñoz-Ávila Luis Javier Martínez-González Cristina Lucía Dávila-Fajardo Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients
description	High myopia is an ophthalmic pathology that affects half of the young adults in the United States and Europe and it is predicted that a third of the world’s population could be nearsighted at the end of this decade. It is characterized by at least 6 diopters or axial length > 26 mm and, choroidal neovascularization (CNV) in 5 to 11% of cases. Ranibizumab is a recombinant humanized monoclonal antibody fragment. It is an anti-vascular endothelial growth factor (anti-VEGF) drug used in the treatment of CNV. Many genetic polymorphisms have been associated with interindividual differences in the response to ranibizumab, but these associations were not yet assessed among patients with high myopia and CNV. We performed a retrospective study assessing the association of genetic polymorphisms with response to ranibizumab in patients with CNV secondary to high myopia (mCNV). We included genetic polymorphisms previously associated with the response to drugs used in CNV patients (bevacizumab, ranibizumab, aflibercept, and photodynamic therapy (PDT)). We also included genetic variants in the <i>VEGFA</i> gene. Based on our results, <i>ARMS2</i> (rs10490924) and <i>CFH</i> (rs1061170) are associated with response to ranibizumab in high myopia patients; and, included <i>VEGFA</i> genetic polymorphisms are not associated with ranibizumab response in our population but might be related to a higher risk of CNV.
format	article
author	David Blánquez-Martínez Xando Díaz-Villamarín Alba Antúnez-Rodríguez Ana Pozo-Agundo José Ignacio Muñoz-Ávila Luis Javier Martínez-González Cristina Lucía Dávila-Fajardo
author_facet	David Blánquez-Martínez Xando Díaz-Villamarín Alba Antúnez-Rodríguez Ana Pozo-Agundo José Ignacio Muñoz-Ávila Luis Javier Martínez-González Cristina Lucía Dávila-Fajardo
author_sort	David Blánquez-Martínez
title	Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients
title_short	Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients
title_full	Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients
title_fullStr	Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients
title_full_unstemmed	Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients
title_sort	genetic polymorphisms affecting ranibizumab response in high myopia patients
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/4adc7064e37c439eaf52b26c7a335386
work_keys_str_mv	AT davidblanquezmartinez geneticpolymorphismsaffectingranibizumabresponseinhighmyopiapatients AT xandodiazvillamarin geneticpolymorphismsaffectingranibizumabresponseinhighmyopiapatients AT albaantunezrodriguez geneticpolymorphismsaffectingranibizumabresponseinhighmyopiapatients AT anapozoagundo geneticpolymorphismsaffectingranibizumabresponseinhighmyopiapatients AT joseignaciomunozavila geneticpolymorphismsaffectingranibizumabresponseinhighmyopiapatients AT luisjaviermartinezgonzalez geneticpolymorphismsaffectingranibizumabresponseinhighmyopiapatients AT cristinaluciadavilafajardo geneticpolymorphismsaffectingranibizumabresponseinhighmyopiapatients
_version_	1718410769075273728

Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients

Ejemplares similares